<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754219</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_HI_I</org_study_id>
    <nct_id>NCT02754219</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction</brief_title>
  <official_title>A Study to Evaluate Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction and Control Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the pharmacokinetics profiles and safety of
      Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral
      dose of Evogliptin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When the future evogliptin be administered to liver dysfunction patients, to investgate
      whether dose adjustment is necessary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2016</start_date>
  <completion_date type="Actual">January 19, 2018</completion_date>
  <primary_completion_date type="Actual">January 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic(Cmax of Evogliptin)</measure>
    <time_frame>Day1, Day2, Day3, Day4, Day5, Day6</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>Evogliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic dysfunction, Healthy control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin</intervention_name>
    <description>DPP4-inhibitor, Evogliptin</description>
    <arm_group_label>Evogliptin</arm_group_label>
    <other_name>DA-1229</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &lt;Hepatic Dysfunction&gt;

          -  At least 6 months with chronic liver disease (Regardless of cause hepatic dysfunction)

          -  Child-Pugh A or B

        &lt;Healthy Control&gt;

          -  Subject has the following conditions: age ± 5 years, BMI ± 20%, same sex of each
             matched hepatic dysfunction subject

        Exclusion Criteria:

        &lt;Hepatic Dysfunction&gt;

          -  Child-Pugh C

          -  History of Liver transplant

        &lt;Healthy Control&gt;

          -  History of chronic liver disorders

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

